Transparency Life Sciences (TLS) is a web-enabled bio-pharmaceutical company. Our mission is to develop medicines for significant unmet medical needs, using a fundamentally superior approach compared to current industry standards. Initially, TLS will focus on acquiring and re-directing the development of compounds that have demonstrated a signal of efficacy, and a clean safety profile, but are on the shelf as a result of poor alignment with the owner's corporate strategy, unsuitable properties for the current indications of interest, or financial reasons.
TLS seeks to divest or partner its products to third parties (including relevant pharmaceutical or biotechnology companies) after having substantially increased their value through mid-stage development. Product commercialization activities will not be supported by TLS in the near term. In some cases (e.g. orphan indications, or where the cost of incremental development is low) TLS may consider advancing compounds into later development stages and registration activities.
Transparency Life Sciences will develop products using a game-changing approach based on three pillars:
The Value of Collaborative Intelligence:
The value of this approach to product design has been well proven in software (Linux), and many other industries. It is increasingly recognized as a valuable method in basic research and drug discovery. However, no company has adopted cIQ as a way to design, execute, and analyze clinical studies -- the crucial part of developing new treatments! Anyone, anywhere, will be able to contribute to the planning and design of TLS compound development strategies and tactics in real-time. By granting full data access to broad expertise, the TLS open source approach will add substantial value to its pipeline of products, which benefits patients, physicians and TLS stakeholders, partners, and product acquirers.
The Value of Data Transparency:
In contrast to the historical approach taken by pharma companies in most aspects of their business, TLS believes that the benefits of working in a transparent environment far outweigh the risks. Pfizer, Merck, Lilly and others have recognized this value, and launched open source efforts in early research to supplement their internal discovery efforts. TLS, however, believes that transparency should facilitate every step of its business process from evaluating and selecting compounds for acquisition, developing the clinical plan and study protocols, recruiting and executing studies, processing, analyzing and interpreting data, regulatory and reimbursement discussions, and ultimately making decisions related to potential asset sales.
The Value of Converging Information Technology with Drug Development Know-How:
The highly innovative, flexible, and scalable TLS IT platform will allow the integration of multiple data inputs from the best of today's medical device technologies and analytical tools to enlarge and enhance the resulting study database and allow a fully transparent approach to be taken in all aspects of the development process. TLS will leverage the opportunities presented by today's growing open source Internet environment for idea generation, planning, analysis and interpretation of data, removing the necessity to retain and/or build a large amount of internal expertise and a high fixed cost base. TLS leverages opportunities for cIQ and cost efficiency offered by the Internet and other modern technologies / techniques such as telemedicine, adaptive trial design, and Bayesian statistics.
TLS Competitive Advantage:
By utilizing collaborative intelligence, data transparency, and converging drug development know-how with modern information technology and telecommunication capabilities, TLS will advance a proprietary portfolio of high-value compounds rapidly and more efficiently through clinical development, using a system that will yield multiple benefits to customers and investors alike. Dramatically reduced time-lines and costs, increased quantity and enhanced quality of data, reduced clinical safety risk, reduced overall investment risk, and enhanced trust in TLS and its products are all expected outcomes of the TLS approach. The TLS pipeline will consist of pharmaceutical compounds in the beginning of mid-stage development -- a key inflection point where the potential for significant value creation is greatest.
Benefits of TLS to Pharma
Enhanced Clinical Trials:
Crowdsourcing channels global Internet accessibility to bring a large number of smart people together to solve well-sculpted challenges. Attracted by incentives appealing to a broad range of stakeholders, participants are given a discrete period of time to investigate, consider, and solve a compelling challenge, and a spirit of collaborative improvement catalyzes further participation. Through crowdsourcing, members meet like-minded peers, and gain attention for their creativity, in an open forum.
